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Abstract
Background
Tumor cell lines that can be tracked in vivo during tumorigenesis and metastasis provide vital
tools for studying the specific cellular mechanisms that mediate these processes as well as
investigating therapeutic targets to inhibit them. The goal of this study was to engineer
imageable mouse mammary tumor cell lines with discrete propensities to metastasize to bone
in vivo. Two novel luciferase expressing cell lines were developed and characterized for use
in the study of breast cancer metastasis to bone in a syngeneic mouse model.

Results
The 4T1.2 luc3 and 66c14 luc2 cell lines were shown to have high levels of bioluminescence
intensity in vitro and in vivo after orthotopic injection into mouse mammary fat pads. The
4T1.2 luc3 cell line was found to closely model the sites of metastases seen in human patients
including lung, liver, and bone. Specifically, 4T1.2 luc3 cells demonstrated a high incidence
of metastasis to spine, with an ex-vivo BLI intensity three orders of magnitude above the
commercially available 4T1 luc2 cells. 66c14 luc2 cells also demonstrated metastasis to
spine, which was lower than that of 4T1.2 luc3 cells but higher than 4T1 luc2 cells, in
addition to previously unreported metastases in the liver. High osteolytic activity of the 4T1.2
luc3 cells in vivo in the bone microenvironment was also detected.

Conclusions
The engineered 4T1.2 luc3 and 66c14 luc2 cell lines described in this study are valuable tools
for studying the cellular events moderating the metastasis of breast tumor cells to bone.
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Background
Metastasis of breast carcinoma cells from the primary tumor to secondary organ sites such as
lung, liver, brain, and bone is the leading cause of mortality in patients with breast cancer [1].
Bone is the most frequent site of metastasis in breast cancer patients, observed in
approximately 65 to 75% of patients with metastatic breast cancer [2]. Bone metastases often
cause significant pain and morbidity in these patients due to osteolysis and bone resorption,
and the median survival time after detection these metastases is approximately two years
[3,4].
Researchers studying breast tumorigenesis and metastatic progression in vivo utilize several
types of mouse models including transgenic, xenograft, and syngeneic mouse models.
Transgenic mouse models that generate spontaneous mammary tumors have been developed
using promoters such as the mouse mammary tumor virus (MMTV) promoter to drive
oncogenes, including polyoma middle T antigen (MMTV-PyMT) and ErbB2/Neu (MMTVNeu) (for review see [5]). Transgenic mice lacking the p53 tumor suppressor gene (p53 −/−),
which is mutated in 40-50% of human breast cancers, have also been utilized extensively in
cancer studies but do not reproducibly form mammary tumors [6]. A major drawback to these
transgenic models, along with the commonly used C3(1)-SV40 T-antigen transgenic mice
that also develop mammary tumors independent of steroid supplementation, is that bone
metastases cannot be detected (for review see [7]). Given that these tumors occur
spontaneously via transformation of the host’s normal cells that do not have specific,
imageable cellular tags, it is very difficult to track these cells in vivo during tumor
progression and metastasis.
In the xenograft mouse model, human breast cancer cells are injected into
immunocompromised, athymic mice. This model is useful because it allows breast cancer
cells of human origin to be studied. However, when studying the metastatic cascade in these
models, in which the host organism and the implanted tumor cells are not of the same species,
important tumor and host stromal interactions may be disrupted due to interspecies signaling
incompatibilities [8]. Additionally, due to the compromised immune system of the athymic
mouse, immune-mediated tumor and host stromal interactions important for metastasis may
be lost in this model (for review see [9]).
Syngeneic models in which the tumor cells are placed into the same species they originated
from, and therefore the tumor microenvironment is of the same species, are able to overcome
limitations of both xenograft and transgenic models in studying metastasis. Commonly used
syngeneic mouse models of breast cancer utilize cells isolated from mammary tumors that

occurred spontaneously in wild-type Balb/c mice. These cells can then be injected
orthtopically into Balb/c mice and will reproducibly grow a mammary tumor. Currently, there
is a series of mouse mammary cancer cell lines derived from the spontaneous breast tumors
of Balb/c mice including non-metastatic 67NR cells, 66c14 cells that metastasize to lung, and
4T1 cells that metastasize to lung and liver [10]. 4T1.2 cells are a sub-clone of the original
osteolytic 4T1 mammary tumor cell line that have been selected for their increased
propensity to metastasize to bone [10]. While 66c14 cell metastasis is restricted to the lymph
nodes and lung, 4T1.2 cells closely resemble the metastatic profile in humans with metastasis
to the bone, lymph nodes, and lung [10,11]. Additionally, the 4T1.2 orthotopic model results
in an increase in hypercalcemia due to osteolysis, an important characteristic that resembles
human bone metastasis [12]. Engineering these mouse cells to be traceable and imageable in
a live animal make them even more valuable for studying metastasis to bone in vivo in a
syngeneic mouse model.
Currently, there are several human breast cancer cell lines engineered to express
bioluminescence imaging (BLI) tags such as luciferase (luc) that can be used to track the
metastases of these cells in vivo. These cell lines include MDA-MB-231-luc2 and MCF-7luc2, both available commercially (Caliper Life Sciences, Hopkinton, MA). In general,
human mammary cancer cells utilized in xenograft mouse models of breast cancer
demonstrate a low propensity to metastasize to bone unless introduced via intra-cardiac
injection, which bypasses critical initial steps in the metastatic cascade (for review see [13]).
To date, there are only two mouse mammary cancer cell lines commercially available that
stably express the luc gene, 4T1-luc2 and 4T1-luc2-GFP cells, available from Caliper Life
Sciences (Hopkinton, MA, USA).
In this study we generated by transfection of 66c14 and 4T1.2 mouse mammary carcinoma
cells with the pGL4 vector two new cell lines that stably express the luciferase gene. These
two cell lines, referred to as 66c14 luc2 and 4T1.2 luc3, produce high levels of
bioluminescence in vitro and in vivo. Additionally, tumor progression in vivo was consistent
with the parental 66c14 and 4T1.2 cell lines. Importantly, the overall metastatic burden,
quantified as the number and photon density of BLI areas, was higher in mice injected
orthotopically with the 4T1.2 luc3 cells as compared to both 66c14 luc2 cells and the
commercially available 4T1 luc2 cells (Caliper Life Sciences, Hopkinton, MA). In vivo and
ex vivo imaging of metastasis showed that the 4T1.2 luc3 cells had a statistically significant
higher level of metastases to the spine and lung as compared to the 66c14 luc2 cells, which
nonetheless showed detectable levels of spine and lung metastases. Therefore, the newly
established 4T1.2 luc3 and 66c14 luc2 cell lines are reliable tools for monitoring and
quantifying breast cancer metastasis to bone and other organs as well as for studying the
signaling pathways associated with these processes.

Results
Establishment and characterization of 66c14 and 4T1.2 mouse mammary
carcinoma cell lines that stably express luciferase
Of the five different 66c14 luc lines produced, 66c14 luc5 cells produced the highest
bioluminescence intensity, 1,019 photons/sec/cell, and the 66c14 luc2 cells produced the
second highest, 945 photons/sec/cell (Figure 1A, green bar). Of the five different 4T1.2 luc
lines produced, 4T1.2 luc3 cells produced the highest level of bioluminescence intensity, at

2,070 photons/sec/cell (Figure 1B, green bar). Two cell lines, 66c14 luc1 (105
photons/sec/cell) and 4T1.2 luc5 (150 photons/sec/cell), had bioluminescence intensities
below the minimum detection limit (MDL) for in vivo imaging (~300 photos/sec/cell; Caliper
Life Sciences) and were not utilized in the following in vivo studies. The other eight lucexpressing cell lines generated in 4T1.2 and 66c14 cells were further assessed for in vivo BLI
based on in vitro bioluminescent intensities at least twice the in vivo MDL.
Figure 1 Bioluminescence intensities of 66c14 luc- and 4T1.2 luc-expressing cell lines in
vitro. Image analysis show bioluminescence from clonal populations of (A) 66c14 luc(1–5)
cells and (B) 4T1.2 luc(1–5) cells. Green bars highlight 4T1.2 luc3 and 66c14 luc2 clones
with high mean bioluminescence values. Data is expressed as photons/sec/cell (mean ± std
dev, n = 4) calculated by comparing each cell line to known values of HeLa-Luc cells (350
photons/sec/cell; see Materials and Methods)

In vivo tumor growth of 66c14 luc2 and 4T1.2 luc3 cells
To confirm that the luc-expressing cell lines grow in vivo in a manner comparable to the
parental cells, tumor growth was monitored. 1 × 105 cells (parental 66c14, 66c14 luc2, 66c14
luc3, 66c14 luc4, and 66c14 luc5 or parental 4T1.2, 4T1.2 luc1, 4T1.2 luc2, 4T1.2 luc3, and
4T1.2 luc4) were injected into the mammary fat pad of female Balb/c mice (n = 3 per cell
line) (Figure 2). Tumor size was measured using calipers twice a week for up to 36 days and
expressed as tumor volume (mm3) = (length × width2/2) [11]. Mice injected with 66c14 luc2
cells (Figure 2A; green) displayed a tumor growth pattern similar to that of mice injected
with parental 66c14 cells (Figure 2A; red). In vivo analysis of 66c14 luc3 cells demonstrated
a small reduction in maximum tumor volume compared to parental 66c14 cells but did not
produce bioluminescence in vivo (Figure 2A, Figure 3). Mice injected with 66c14 luc4 or
luc5 cells (the cells with high BLI intensities in vitro) had severely reduced tumor growth in
vivo (Figure 2A, Figure 3). Injection of 4T1.2 luc3 cells (the cells with the highest BLI
intensity in vitro; Figure 2B; green) resulted in a tumor growth pattern similar to that of
parental 4T1.2 cells (Figure 2B; red). 4T1.2 luc1, luc2, and luc4 cell injections all resulted in
reduced tumor progression in vivo (Figure 2B, Figure 3). Overall, 66c14 luc2 and 4T1.2 luc3
cell lines demonstrated tumor progression most consistent with parental cell lines.
Figure 2 Tumor growth of 66c14 luc and 4T1.2 luc cells injected orthotopically into
Balb/c mice. 66c14 luc and 4T1.2 luc cell lines were injected into the mammary fat pad of
Balb/c mice and tumor volume was measured over 36 days. (A) 66c14 luc2 tumor growth
(green/square) was most consistent with parental 66c14Tumor growth (red/circle) and (B)
4T1.2 luc3 tumor growth (green/square) was most consistent with parental 4T1.2 (red/circle)
tumor growth. Data is expressed as tumor volume (mm3) (mean ± std dev; n = 3)
Figure 3 Summary of in vitro and in vivo analysis of luc-expressing 4T1.2 and 66c14 cell
lines.
Next, BLI intensity of 66c14 luc and 4T1.2 luc cells during tumor growth was assessed in
vivo. Tumors from injected 66c14 luc2 cells produced the highest level of BLI intensity of all
the 66c14 luc cells, averaging 8.29 × 109 photons/second on day 25 after tumor cell
injection (Figure 4A; green, Figure 3). Tumors from injected 4T1.2 luc3 cells produced the
highest level of BLI intensity of all the 4T1.2 luc cells, averaging 4.84 × 106
photons/second on day 25 after tumor cell injection (Figure 4B; green, Figure 3). Sequential
images on days 18, 25, 32, and 39 of mice injected with the 66c14 luc2 cell line showed

increasing BLI intensity at the tumor site correlating with increasing tumor size (Figure 4C).
The BLI intensity of tumors from mice injected with 4T1.2 luc3 cells started to decrease after
day 25, likely due to the tumor-associated necrosis (Figure 4D).
Figure 4 BLI of 66c14 luc and 4T1.2 luc cells in vivo. Tumor bioluminescence intensities
from each of the (A) 66c14 luc and (B) 4T1.2 luc tumor-bearing mice on day 25 after tumor
cell injection are shown. 66c14 luc2 and 4T1.2 luc3 exhibited the highest BLI intensity in
vivo (green bars). Sequential images of (C) 66c14 luc2 and (D) 4T1.2 luc3 tumor-bearing
mice imaged ventrally by BLI once a week for 4 weeks are shown. 66c14 luc2 tumors
continued to grow while 4T1.2 luc3 tumors became necrotic between day 25 and 32. Data
expressed as photon/sec (mean ± std dev; n = 3)

BLI of metastases from mice injected with 66c14 luc2 or 4T1.2 luc3 cells
The 66c14 luc2 and 4T1.2 luc3 cell lines were chosen for additional investigation of
metastatic potential due to their consistently similar tumor growth profiles with the parental
cell lines, and high levels of BLI intensity in vivo. These two new cell lines were compared to
the 4T1 luc2 cell line purchased from Caliper Life Sciences described previously [14].
Independent orthotopic injection of each of these three cell lines (1 × 105 cells) into the
mammary fat pad of female Balb/c mice (n = 3) resulted in palpable tumors at day 14 after
injection. Mice injected with the 66c14 luc2, 4T1.2 luc3, or 4T1 luc2 cells were imaged once
the mice had reached endpoint criteria of maximum metastases including a loss of activity
and 10% of their body weight (32 days after injection for the 66c14 luc2 and 4T1.2 luc3
injected mice and 28 days for the 4T1 luc2 injected mice).
In the dorsal and ventral whole body BLI images, the 66c14 luc2 and 4T1.2 luc3 cells were
visible in the primary tumors and numerous secondary metastatic regions in vivo using a BLI
intensity imaging scale on the order of 106 photons/sec/cm2 (highlighted with a yellow box in
Figure 5A). On the other hand, in whole body BLI images of mice injected with the
commercially available 4T1 luc2 cells only primary tumors were visible. The high
bioluminescence produced by the 4T1 luc2 primary tumor was imaged using a scale on the
order of 108 photons/sec/cm2 (highlighted with a red box in Figure 5A), and likely prohibited
secondary sites of metastases to be visualized.
Figure 5 Metastasis of 66c14 luc2, 4T1.2 luc3, and 4T1 luc2 cells in vivo. Representative
(A) whole animal and (B) ex vivo organs from mice injected with the 66c14 luc2 (left), 4T1.2
luc3 (middle), or commercially available 4T1 luc2 (right) cells, 4–5 weeks after injection are
shown. Primary tumor bioluminescence intensities were visualized in animals injected with
all cell types in both dorsal and ventral views. Bioluminescence was also detectable in the
thoracic region of the 66c14 luc2 and 4T1.2 luc3 animals correlating with ex vivo
bioluminescence from metastatic lesions detected in lung and spine. No bioluminescence
representing metastatic lesions was detected in mice injected with 4T1 luc2 cells. The
bioluminescence intensity of the primary tumor from the 4T1 luc2 mouse represented was
very high and likely prohibited secondary sites of metastasis from being visualized. The BLI
scale next to the whole body image of the 4T1 luc2 injected mouse (highlighted in red)
reflects this difference. All other images (highlighted in yellow) are presented with a
consistent BLI scale. Overall, the 4T1.2 luc3 cells showed the highest levels of BLI from
metastases both in vivo and ex-vivo

Ex vivo analyses were also performed in order to identify specific tissues where metastases
formed. BLI revealed 66c14 luc2 ex vivo metastases primarily to lung, although metastases to
liver and spine were detectable, while 4T1.2 luc3 cells were highly metastatic to lung, liver
and spine (Figure 5B, Figure 3). Mice injected with the commercially available 4T1 luc2 cells
showed weak ex vivo BLI intensities from metastases in the lung, liver, and spleen, and no
spine metastases were measured using the same scale as with the 66c14 luc2 and 4T1.2 luc3
cells (Figure 5B, yellow box; Figure 3).
Quantification of the BLI intensities from spines, lung, and liver ex vivo from mice injected
with 66c14 luc2, 4T1.2 luc3, and 4T1 luc2 cells were performed. Results showed that spines
excised from the 4T1.2 luc3 group had BLI intensities 10-fold higher than the 66c14 luc2
group and three orders of magnitude (103) higher than that of the 4T1 luc2 injected group
(Figure 6A). Lungs from mice injected with either 66c14 luc2 or 4T1.2 luc3 cells had a mean
BLI intensity an order of magnitude higher than the 4T1 luc2 (Figure 6B). Interestingly, one
of the mice injected with 66c14 luc2 cells also showed a high average BLI intensity from
multiple metastases in the liver, never previously reported in the parental 66c14 cell line
(Figure 6C). Overall, the metastatic burden, which accounts for the average number and size
of metastases, detected in vivo and ex vivo was highest for 4T1.2 luc3 cells. In terms of their
ability to be tracked in the primary tumor and secondary metastatic sites in vivo and ex vivo,
both 4T1.2 luc3 and 66c14 luc2 cells showed higher BLI intensities than 4T1 luc2 cells.
Figure 6 Quantification of BLI intensity from ex-vivo 66c14 luc2, 4T1.2 luc3, and 4T1
luc2 metastatic organs. Bioluminescence intensities were quantified ex vivo in (A) spine,
(B) lung, and (C) liver of mice orthotopically injected with 66c14 luc2 (white bars), 4T1.2
luc3 cells (black bars), or 4T1 luc2 (grey bars), 32 days (4T1.2 luc3 and 66c14 luc2) or
28 days (4T1 luc2) or after tumor cell injection. Spines from mice injected with 4T1.2 luc3
cells showed significantly higher BLI intensity as compared to both 66c14 luc2 and 4T1 luc2
injected mice. Data expressed as photons/sec/cm2 (mean ± SEM; n = 3-4, *p < 0.05, unpaired
t-test)

Micro-computed tomography (Micro-CT) analysis of 4T1.2 luc3 cells
To identify whether 4T1.2 luc3 cells are osteolytic by comparison to the commercially
available 4T1 luc2 cells, each of the cell lines were injected into the tibia of 6-week old
female Balb/c mice and analyzed for bone integrity using micro-CT. Whole body and ex vivo
BLI analysis of mice injected with 4T1.2 luc3 and 4T1 luc2 cells verified the presence of
tumor cells 18 days after injection into the tibia (Figure 7A). Micro-CT analysis showed
significant osteolytic activity of both cell lines near the injection site at the proximal tibia
(Figure 7B-i) and normal bone at the distal tibia (Figure 7B-ii). 66c14 luc2 cells were not
analyzed for osteolytic potential in this study. Overall, these results suggest that 4T1.2 luc3
cells are a useful model for studying osteolytic bone metastasis originating from a primary
breast tumor.
Figure 7 4T1.2 luc3 cells are osteolytic in vivo. (A) 1 × 104 4T1.2 luc3 (left) or 4T1 luc2
cells (right) were injected into the proximal end of the left tibia of a 6-week old female Balb/c
mice and visualized after i.p. injection of 150 mg/kg D-Luciferin using an IVIS Spectrum
BLI system (day 18 after tumor cell injection). Whole body ventral view shows luciferase
activity from tumor cells in the left tibia, validated with ex-vivo imaging of the tibia. (B)
micro-CT images of cross sectional slices (4000 × 4000 pixels) (i) at the proximal and (ii)
distal ends of the tibia reveal extensive osteolytic bone degradation (osteolytic damage

highlighted with white arrows) near the injection site. Micro-CT images scanned using a
Microphotonics Skyscan 1172 CT at a 6μm resolution and reconstructed using ImageVis3D
imaging software

Discussion
This study presents two new luciferase-expressing mouse cell lines (66c14 luc2 and 4T1.2
luc3 cells) useful for the in vivo study of breast cancer metastasis to bone. Using BLI, these
cell lines demonstrate greater bone metastatic potential in a syngeneic Balb/c mouse model
than the commercially available 4T1 luc2 cell line (Caliper Life Sciences, Hopkinton, MA).
The 4T1.2 luc3 cell line is metastatic to the lung, liver, and bone in 100% of the mice tested,
and the 66c14 luc2 cell line is highly metastatic to lung and less metastatic to bone based on
BLI intensities. Each of the two cell lines showed in vitro growth rates (data not shown) and
in vivo tumor sizes similar to the parental 4T1.2 and 66c14 cell lines.
Lung and bone are the predominant destinations of metastatic 4T1.2 cells [10,11]. However,
here we report detectable metastases in the liver of mice injected with the 4T1.2 luc3 cell line
as well as the 66c14 luc2 cell line, a site of metastases never previously identified with the
parental 4T1.2 or 66c14 cells although demonstrated with the 4T1 cells [10]. It is possible
that these cells have increased metastatic potential due to incorporation of the luciferase gene
and/or due to the transfection and clone selection process. This increased metastatic potential
displayed by the luciferase-expressing cell lines is further supported by our ability to detect
low levels of bioluminescence from the spines of mice treated with the 66c14 luc2 cells,
when previous studies have not shown detectable metastases to bone using the parental 66c14
cell line [10]. However, it is important to note that the bioluminescence intensity from
metastatic 4T1.2 luc3 cells in the spine was nearly ten-fold greater than that of the 66c14 luc2
cells and three orders of magnitude greater (103) that that of the 4T1 luc2 cells, although the
number of metastases detected was similar for all three cell lines (data not shown). This could
be partially explained by differences in tumor growth rate and size at the endpoint of the
experiment of mice injected with the 4T1.2 luc3 cells compared to the 66c14 luc2 or 4T1
luc2 cells (data not shown). In general, a slower progression of the primary tumor has been
correlated with increased metastasis in mouse models [5].
Orthotopically injected 66c14 luc2 or 4T1.2 luc3 cells outperformed 4T1 luc2 cells in wholebody BLI for the detection of metastases. Bioluminescence was detected in the thoracic and
abdominal regions of whole mouse images suggesting that metastasis of 66c14 luc2 and
4T1.2 luc3 cells had occurred. This was verified by the presence of metastases in the lungs,
spine, and liver ex vivo. There was no bioluminescence detected in these regions of the mice
injected with the 4T1 luc2 cells using IVIS instrument settings appropriate for visualizing the
primary tumor. Although there were verified metastases detected in the lung, spine, and liver
by ex vivo imaging from mice injected with the 4T1 luc2 cells, the intensities were several
orders of magnitude lower than the primary tumor. It is important to note that the much
higher luminescence of the 4T1 luc2 primary tumor makes bioluminescence visualization and
quantification of secondary sites of metastasis in the whole mouse difficult.
To establish an in vivo model system where the number of metastatic sites was increased by
bypassing initial steps of the metastatic cascade, intra-cardiac injections were performed.
Injection of 4T1.2 luc3 cells into the left ventricle resulted in cell migration to and
colonization in lung, liver, spine, brain, spleen, and kidneys (data not shown). The same

metastatic sites were seen with 4T1 luc2 cells and a similar pattern was seen with 66c14 cells,
with the exception of spleen and brain (data not shown). Therefore 4T1.2 luc3 cells are
particularly useful for investigations of mammary tumor metastatic sites including brain and
kidney if administered via intra-cardiac injection.
Intra-tibial injections of 4T1.2 luc3 and 4T1 luc2 cells were performed to evaluate the
osteolytic nature of these cells. Parental 4T1 cells have been extensively characterized in vivo
for their osteolytic activity in bone [15-17], while no previous publications address either
parental 4T1.2 or 4T1 luc2 cells. Our results demonstrated that both 4T1.2 luc3 and 4T1 luc2
cells have similar osteolytic activity in vivo (Figure 6). Therefore, these cells are useful in
BLI and 3-D bone morphology studies performed in tandem investigating not only
metastasis, but also the osteolytic capacity of mammary tumor cells.

Conclusions
The purpose of this study was to incorporate the luciferase gene into previously characterized
mouse mammary tumor cell lines with discrete bone metastatic profiles in order to track
metastases in vivo using BLI. We show that the highly metastatic 4T1.2 luc3 cell line, when
injected orthotopically, closely models the sites of metastases seen in human patients
including lung, liver, and bone. These cells show osteolytic activity in vivo and the ability to
proliferate in additional organ sites such as brain, spleen, and kidneys. We also present results
demonstrating a phenotypically similar 66c14 luc2 cell line that shows similar metastases in
the lung as the 4T1.2 luc3 cell line along with previously unreported metastases in bone.
These imageable cells lines are powerful tools for identifying mechanisms important for
breast cancer metastasis to bone in vivo.

Methods
Cells lines and cell culturing
66c14 and 4T1.2 cells were cultured and maintained in α-MEM supplemented with 10% fetal
bovine serum, 1 mM Penicillin/Streptomycin, and 1 mM sodium pyruvate at 37°C in 5% CO2
and 95% humidity. 4T1 luc2 cells were purchased from Caliper Life Sciences (Hopkinton,
MA) and grown according to manufacturer’s instructions.

Stable transfections of cells containing the pGL4 vector
Approximately 2.5 × 105 66c14 and 4T1.2 cells were plated in 6-well culture dishes and
transfected with 5.0 μg of pGL4.13[luc2/SV40]vector (Promega, Madison, WI) using
Lipofectamine LTX (Invitrogen, Carlsbad, CA) per manufacturer’s instructions. The cells
were trypsinized (0.25% trypsin) 48 hours after transfection, diluted, and plated into 96-well
plates. Two weeks after plating, 100 μL media containing D-luciferin (Caliper Life Sciences,
Hopkinton, MA) at a final concentration of 150 μg/mL was added to the 96-well plates.
Visualization of bioluminescence was performed using the Kodak Image Station 4000R
(Eastman Kodak Company, Rochester, NY) with a 5-minute exposure. Bioluminescent cells
were serially diluted into 96-well plates and cells were grown approximately 2 weeks and
assayed for bioluminescence. The colonies with the highest levels of bioluminescence were
diluted to 1 cell/100 μL and plated in 96-well plates, grown, and assayed again for
bioluminescence. To ensure a clonal population, the colonies with the highest level of

bioluminescence were again selected, and the above process was repeated an additional time.
Finally, the colonies with the highest level of bioluminescence were selected and expanded to
obtain clonal populations of 66c14 luc (66c14 luc1 to 66c14 luc5) and 4T1.2 luc (4T1.2 luc1
to 4T1.2 luc5) cells expressing the luciferase gene.

In vitro bioluminescence assay to estimate cell line bioluminescence intensities
Approximately 1 × 105 66c14 luc and 4T1.2 luc cells containing stably expressing the pGL4
vector, as well as control HeLa luc cells (Caliper Life Sciences) were plated in a 24-well
culture dish and incubated overnight. Bioluminescent intensity was measured as described in
the previous section. Using ImageJ software (National Institutes of Health), each captured
image was inverted and total pixel density was calculated. HeLa luc cells, producing
approximately 350 photons/sec/cell, were used as a reference point to estimate the
photons/sec/cell produced by each of the new 66c14 luc and 4T1.2 luc cell lines.

Injection of cells for measuring in vivo bioluminescence imaging (BLI) and
tumor progression
All animal studies were conducted in accordance with the animal component of research
protocol (ACORP) #JOR0010 protocol approved by the Institutional Animal Care and Use
Committee (IACUC) at the Boise VA Medical Center, Boise, ID. 1 × 105 cells suspended in
10 μL of phosphate buffered saline (PBS) were injected into the 4th mammary fat pad of 7week old female Balb/c mice (n = 3/group). Ten different groups of cells were injected
including parental (control) 66c14, 66c14 luc2, 66c14 luc3, 66c14 luc4, 66c14 luc5, parental
(control) 4T1.2, 4T1.2 luc1, 4T1.2 luc2, 4T1.2 luc3, and 4T1.2 luc4 cells. Tumor size was
measured with calipers bi-weekly once tumors became palpable (after approximately
2 weeks). BLI of live animals was initiated at 18 days after cell line injection and performed
weekly. Briefly, mice were injected i.p. with 150 mg/kg of D-luciferin (Caliper Life
Sciences) in PBS, anesthetized with 2.5% isoflurane, and imaged. Mice were imaged using a
charge-coupled device camera–based bioluminescence imaging system (IVIS Spectrum,
Caliper Life Sciences; exposure time 1–300 sec, binning 4/8/16, field of view 23 cm, f/stop 1,
emission filter open). Signal was measured and recorded as total flux (photons/sec).
Corresponding grayscale photographs and color luciferase images were automatically
superimposed and analyzed with Living Image software (Xenogen Biosciences Corporation,
Cranbury, NJ).
Mice utilized for metastasis investigations were treated exactly as above with the following
modifications. Three mice per cell line were orthotopically injected with 66c14 luc2, 4T1.2
luc3, or 4T1 luc2 cells. Whole animals were imaged 4–5 weeks following tumor cell injection
and immediately injected with a second dose of 150 mg/kg of D-luciferin. Ten minutes
following this injection the mice were euthanized with isoflurane gas followed by cervical
dislocation, and the lungs, spine, spleen, and liver were dissected and imaged ex vivo using
the bioluminescence imaging system (exposure time 1–300 sec, binning of 4/8/16, field of
view 23 cm, f/stop of 1, emission filter open).

Micro-computed tomography (Micro-CT)
In order to verify the osteolytic potential of the 4T1.2 luc3 cells, 1 × 104 cells in 100 μL of
PBS were injected into the left tibia of a 6-week old female Balb/c mouse. In vivo

bioluminescence was determined as stated above. Immediately following ex-vivo imaging of
the tibia, it was placed in 10% formalin overnight and stored in 70% ethanol for analysis.
Micro-CT analysis was conducted using a Microphotonics Skyscan 1172. A 6.6 μM
resolution was used for image collection of 2D scans (4000 × 4000 pixels) and ImageVis3D
imaging software (www.imagevis3d.org) for 3D reconstructions.
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Figure 3

* lndictes cells were not injected into mice due to low in vitro lummescence.
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